Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456298 | 0.78 | MAPK1 (0.57) | MAPK1L3MBTL1KDM4ENNMTTP53 | |
| SCHEMBL29442775 | 0.78 | MAPK1 (0.57) | MAPK1L3MBTL1KDM4ENNMTTP53 | |
| SCHEMBL20912018 | 0.78 | MAPK1 (0.47) | MAPK1L3MBTL1KDM4ENNMTTP53 | |
| SCHEMBL8175471 | 0.77 | MAPT (0.46) | L3MBTL1KDM4ETP53MAPTCYP1A2 | |
| SCHEMBL31044569 | 0.73 | MAPK1 (0.54) | MAPK1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL2721535 | 0.73 | MAPK1 (0.54) | MAPK1L3MBTL1KDM4EMAPTKMT2A | |
| SCHEMBL155925 | 0.73 | MAPK1 (0.54) | MAPK1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL3752771 | 0.72 | MAPK1 (0.35) | MAPK1KDM4ETP53MAPTHSD17B10 | |
| SCHEMBL24078823 | 0.72 | NNMT (0.36) | KDM4ENNMT | |
| SCHEMBL29598289 | 0.72 | NNMT (0.36) | KDM4ENNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023103850-A1 | SMALL MOLECULE STING AGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION | 中国科学院上海药物研究所 | 2023-06-15 | — | — | WO | disclosed |
| US-20220288065-A1 | MONOCYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE | 2022-09-15 | — | — | US | disclosed |
| CN-114981256-A | Single-ring agonists of the interferon gene stimulator STING | 斯克里普斯研究学院 | 2022-08-30 | — | — | CN | disclosed |
| EP-4017592-A1 | MONOCYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | The Scripps Research Institute (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035257-A1 | MONOCYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021035257-A1 | MONOCYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288065-A1 | MONOCYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | STING1, IRF3, CGAS | MAPK1 3141/4885L3MBTL1 4203/4885KDM4E 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.